Immunity, inflammation, and cancer.

Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34

EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27

Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37

Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31

Four faces of cellular senescence. J Cell Biol (2011) 6.86

The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol (2012) 5.60

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34

Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15

Aging, cellular senescence, and cancer. Annu Rev Physiol (2012) 5.08

Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98

Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med (2011) 4.91

Linear ubiquitination prevents inflammation and regulates immune signalling. Nature (2011) 4.85

Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57

Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41

Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell (2012) 4.16

IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer (2010) 4.08

Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02

Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95

Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91

Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80

Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76

The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer (2012) 3.75

Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst (2012) 3.69

Molecular mechanisms of cancer development in obesity. Nat Rev Cancer (2011) 3.65

Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 3.59

Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57

Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLoS Biol (2014) 3.46

Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature (2014) 3.31

Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell (2014) 3.29

Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell (2012) 3.24

VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23

Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol (2011) 3.20

Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med (2011) 3.12

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06

Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology (2014) 3.06

Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation. PLoS Biol (2010) 2.99

Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94

The microbiome and cancer. Nat Rev Cancer (2013) 2.86

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol (2015) 2.85

NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A (2011) 2.74

Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci U S A (2010) 2.74

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med (2012) 2.71

Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 2.71

Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell (2011) 2.70

Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell (2014) 2.66

Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci U S A (2012) 2.61

Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med (2013) 2.60

NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell (2014) 2.56

NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene (2010) 2.56

Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell (2010) 2.50

Cellular senescence: putting the paradoxes in perspective. Curr Opin Genet Dev (2010) 2.49

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47

Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A (2012) 2.42

IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature (2012) 2.36

Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab (2012) 2.34

The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog (2011) 2.30

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24

The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell (2011) 2.18

Survivin and IAP proteins in cell-death mechanisms. Biochem J (2010) 2.18

Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell (2012) 2.16

Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. Cancer Cell (2016) 2.13

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell (2015) 2.10

Obesity, inflammation, and liver cancer. J Hepatol (2011) 2.09

Fibroblast heterogeneity in the cancer wound. J Exp Med (2014) 2.09

Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08

Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A (2011) 2.08

Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling. Nat Immunol (2010) 2.07

The role of JNK in the development of hepatocellular carcinoma. Genes Dev (2011) 2.07

Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol (2012) 2.07

Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05

α-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. Sci Signal (2011) 2.05

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03

Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol (2012) 2.02

The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev (2012) 2.01

IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest (2014) 2.01

Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis. Cell (2016) 1.99

CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell (2012) 1.97

Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer (2013) 1.96

Apoptosis, stem cells, and tissue regeneration. Sci Signal (2010) 1.95

Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol (2013) 1.95

Essentials of Th17 cell commitment and plasticity. Blood (2013) 1.95

The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell (2011) 1.92

Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol (2011) 1.92

Angiotensin II drives the production of tumor-promoting macrophages. Immunity (2013) 1.88

Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity (2014) 1.87

Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature (2015) 1.87

Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol (2012) 1.85

Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci (2011) 1.84

Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin (2013) 1.83

Is HCMV a tumor promoter? Virus Res (2010) 1.81

Tumor promotion via injury- and death-induced inflammation. Immunity (2011) 1.81

STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal (2014) 1.79

Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A (2011) 1.78

IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol (2010) 1.77

Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. J Vasc Interv Radiol (2013) 1.76

MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun (2013) 1.76

Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev (2012) 1.71

ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem cells. J Exp Med (2013) 1.70

Microbiota, disease, and back to health: a metastable journey. Sci Transl Med (2012) 1.70

The hallmarks of cancer. Cell (2000) 113.05

A genetic model for colorectal tumorigenesis. Cell (1990) 44.37

Cancer-related inflammation. Nature (2008) 34.21

The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82

Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell (2008) 28.29

Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54

Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell (1987) 20.61

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53

Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64

Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science (2008) 16.54

IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82

Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57

STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45

NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14

Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell (2008) 14.80

Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91

Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64

Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell (2006) 11.79

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03

Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57

Chronic lymphocytic leukemia. N Engl J Med (2005) 9.99

The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37

Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29

AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer (2003) 8.88

IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78

CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54

A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54

Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47

Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21

Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14

Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04

Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest (1996) 7.97

Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol (2009) 7.74

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 7.55

A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45

The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 7.40

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73

Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67

Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58

IL-23 promotes tumour incidence and growth. Nature (2006) 6.30

Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 6.27

gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell (2009) 6.26

NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature (2008) 6.13

The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell (2007) 6.07

Radical causes of cancer. Nat Rev Cancer (2003) 5.45

Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med (2000) 5.34

Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest (2008) 5.26

The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 5.18

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17

The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity (2003) 5.11

The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer (2005) 5.07

IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05

Immune surveillance of tumors. J Clin Invest (2007) 5.04

Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med (2009) 5.02

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 4.98

Necrotic death as a cell fate. Genes Dev (2006) 4.93

Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell (2009) 4.73

T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69

Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle (2006) 4.67

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer (2001) 4.62

NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56

Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56

TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell (2009) 4.47

Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med (2000) 4.45

Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell (2008) 4.43

Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med (1999) 4.41

Toll-like receptors and cancer. Nat Rev Cancer (2008) 4.29

Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell (2004) 4.23

Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10

Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00

Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature (2008) 3.82

Immune therapy for cancer. Annu Rev Immunol (2009) 3.71

Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68

Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest (2008) 3.37

B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24

Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19

DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest (2008) 3.17

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15

Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat Immunol (2008) 3.14

Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med (2007) 3.11

Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A (2006) 3.02

Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res (2009) 2.98

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96

STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest (2008) 2.95

Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83

A central role for JNK in obesity and insulin resistance. Nature (2002) 17.27

IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82

NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol (2005) 13.98

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91

IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005) 12.07

Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52

NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39

The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol (2004) 10.85

AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10

Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell (2005) 9.16

Regulation and function of IKK and IKK-related kinases. Sci STKE (2006) 8.98

IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78

A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54

Intracellular pattern recognition receptors in the host response. Nature (2006) 8.04

Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04

p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88

Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell (2008) 6.83

Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36

Inflammation and colon cancer. Gastroenterology (2010) 6.32

gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell (2009) 6.26

Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17

NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature (2008) 6.13

Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature (2005) 5.72

The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 5.38

JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab (2007) 5.38

Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 5.25

The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 5.18

NF-κB and the link between inflammation and cancer. Immunol Rev (2012) 4.74

Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature (2007) 4.68

NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61

Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell (2012) 4.58

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57

NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56

Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41

Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33

IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (2005) 4.31

An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29

Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science (2002) 4.26

NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10

Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10

IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07

Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00

Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98

Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell (2004) 3.94

Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science (2010) 3.86

The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med (2003) 3.85

A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell (2004) 3.71

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68

Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science (2004) 3.66

Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58

Redundant pathways for negative feedback regulation of bile acid production. Dev Cell (2002) 3.51

The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell (2008) 3.35

Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A (2006) 3.33

Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J (2004) 3.32

A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A (2008) 3.27

B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24

The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature (2004) 3.18

IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity (2003) 3.12

Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08

Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A (2006) 3.02

Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99

Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science (2008) 2.99

Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell (2008) 2.98

Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell (2010) 2.89

Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis (2011) 2.74

Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology (2008) 2.70

A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64

Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators. Immunity (2005) 2.56

Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol (2005) 2.56

Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol (2009) 2.52

Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci U S A (2006) 2.49

Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48

Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity (2010) 2.47

JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev Cell (2003) 2.45

Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell (2010) 2.43

The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett (2004) 2.41

p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts. Mol Cell (2005) 2.38

Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2009) 2.35

Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity (2006) 2.33

ROS production and NF-κB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell (2013) 2.32

Anthrolysin O and other gram-positive cytolysins are toll-like receptor 4 agonists. J Exp Med (2004) 2.32

Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc Natl Acad Sci U S A (2010) 2.32

p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci U S A (2007) 2.31

Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A (2008) 2.26

CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell (2003) 2.23

I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21

IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature (2004) 2.21

Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci U S A (2004) 2.18

Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum (2009) 2.16

A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology (2012) 2.15

IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep (2009) 2.14

Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J (2003) 2.13